Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology (Baltimore, Md.) Md.), 2020-06, Vol.71 (6), p.2164-2166
Hauptverfasser:	Stuart, Laura, Lambourne, Beth, Turner, Paul, Jones, David E.J., Plummer, Ruth, Cresti, Nicola, Dyson, Jessica K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Cholagogues and Choleretics - administration & dosage Cholangitis, Sclerosing - immunology Cholangitis, Sclerosing - therapy Female Glucocorticoids - administration & dosage Hepatitis - etiology Hepatitis - immunology Hepatitis - therapy Hepatology Humans Immunotherapy Liver Function Tests - methods Melanoma Melanoma - pathology Melanoma - physiopathology Melanoma - therapy Metastases Middle Aged Monoclonal antibodies Neoplasm Staging Pembrolizumab Programmed Cell Death 1 Receptor - antagonists & inhibitors Skin Neoplasms - pathology Skin Neoplasms - physiopathology Skin Neoplasms - therapy Targeted cancer therapy Tomography, X-Ray Computed - methods Treatment Outcome Ursodeoxycholic Acid - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!